Hoth Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Hoth Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2018 to Q3 2024.
  • Hoth Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$2.13M, a 1.88% decline year-over-year.
  • Hoth Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$7.53M, a 20% increase year-over-year.
  • Hoth Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$7.69M, a 30.5% increase from 2022.
  • Hoth Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$11.1M, a 21.5% increase from 2021.
  • Hoth Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$14.1M, a 93.1% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$7.53M -$2.13M -$39.3K -1.88% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$7.49M -$1.65M +$62.8K +3.68% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 -$7.55M -$2.05M +$139K +6.32% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$7.69M -$1.7M +$1.72M +50.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 -$9.42M -$2.09M +$591K +22% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$10M -$1.71M +$591K +25.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 -$10.6M -$2.19M +$468K +17.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$11.1M -$3.42M -$40.8K -1.21% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$11M -$2.68M +$569K +17.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$11.6M -$2.3M +$899K +28.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 -$12.5M -$2.66M +$1.61M +37.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$14.1M -$3.38M -$2.58M -321% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$11.5M -$3.25M -$1.09M -50.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$10.4M -$3.2M -$683K -27.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$9.75M -$4.27M -$2.45M -135% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$7.3M -$803K +$3.11M +79.5% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-30
Q3 2020 -$10.4M -$2.17M -$466K -27.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$9.95M -$2.52M -$1.25M -98.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 -$8.7M -$1.82M -$987K -119% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 -$7.71M -$3.92M -$3.33M -570% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-16
Q3 2019 -$4.38M -$1.7M -$1.08M -174% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 -$3.3M -$1.27M -$504K -66% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$2.8M -$829K -$302K -57.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-13
Q4 2018 -$2.5M -$584K Oct 1, 2018 Dec 31, 2018 10-K 2020-03-02
Q3 2018 -$620K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$763K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 -$528K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.